TRCT
ELOX

Tower Research Capital (TRC)’s Eloxx Pharmaceuticals, Inc. Common Stock ELOX Stock Holding History

Tower Research Capital (TRC)’s Portfolio ELOX Stock Details ELOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,830
Closed -$8.8K – 6408
2023
Q3 		$8.8K Sell
1,830
-649
-26% -$3.63K ﹤0.01% 4302
2023
Q2 		$9.64K Buy
2,479
+62
+3% +$397 ﹤0.01% 4245
2023
Q1 		$7K Sell
2,417
-1,372
-36% -$4.96K ﹤0.01% 4812
2022
Q4 		$7K Buy
3,789
+3,307
+686% +$16K ﹤0.01% 4671
2022
Q3 		$3K Buy
482
+157
+48% +$1.89K ﹤0.01% 5500
2022
Q2 		$4K Buy
325
+287
+755% +$3.96K ﹤0.01% 5327
2022
Q1 		$1K Sell
38
-202
-84% -$3.98K ﹤0.01% 5994
2021
Q4 		$7K Buy
+240
New +$10.5K ﹤0.01% 4988
2021
Q3 		– Sell
-265
Closed -$21K – 6440
2021
Q2 		$21K Buy
265
+183
+223% +$15.3K ﹤0.01% 3864
2021
Q1 		$11K Sell
82
-98
-54% -$15K ﹤0.01% 4340
2020
Q4 		$29K Sell
180
-560
-76% -$68.4K ﹤0.01% 3611
2020
Q3 		$78K Buy
740
+566
+325% +$67.8K ﹤0.01% 3326
2020
Q2 		$21K Buy
174
+121
+228% +$13.7K ﹤0.01% 3664
2020
Q1 		$4K Buy
53
+13
+33% +$2.12K ﹤0.01% 2418
2019
Q4 		$12K Buy
40
+6
+18% +$1.21K ﹤0.01% 2257
2019
Q3 		$6K Sell
34
-13
-28% -$3.7K ﹤0.01% 3263
2019
Q2 		$19K Sell
47
-156
-77% -$65.7K ﹤0.01% 2231
2019
Q1 		$95K Buy
203
+182
+867% +$88.4K 0.01% 1449
2018
Q4 		$10K Buy
+21
New +$11.6K ﹤0.01% 2491
2018
Q3 		– Sell
-214
Closed -$146K – 4402
2018
Q2 		$146K Buy
+214
New +$139K 0.01% 1210

Other funds holding ELOX

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Tower Research Capital (TRC)'s ELOX Position: Q4 2023 in Review

Tower Research Capital (TRC) sold out of Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) in Q4 2023, closing a stake of 1,830 shares — an estimated $8.8K sold.

Tower Research Capital (TRC) first reported a position in ELOX in Q2 2018 and held it in 20 quarters. The position peaked at $146K in Q2 2018. 4 funds tracked by Wall St. Rank hold ELOX as of Q4 2023.

  • Tower Research Capital (TRC) reported no remaining Eloxx Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,830 Eloxx Pharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $8.8K.
  • Tower Research Capital (TRC) first reported a position in Eloxx Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 20 quarters.
  • Tower Research Capital (TRC)'s Eloxx Pharmaceuticals, Inc. Common Stock position peaked at $146K in Q2 2018.
  • 4 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2023, filed 13 Feb 2024.